David A Leske1, Sarah R Hatt1, Suzanne M Wernimont1, Yolanda S Castañeda2, Christina S Cheng-Patel2, Laura Liebermann1, Eileen E Birch3, Jonathan M Holmes4. 1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. 2. Retina Foundation of the Southwest, Dallas, Texas. 3. Retina Foundation of the Southwest, Dallas, Texas; Department of Ophthalmology, UT Southwestern Medical Center, Dallas. 4. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota; Department of Ophthalmology and Vision Science, University of Arizona-Tucson. Electronic address: jmholmes@arizona.edu.
Abstract
PURPOSE: To evaluate eye-related quality of life (ER-QOL) and functional vision across a wide range of pediatric eye conditions, using the Pediatric Eye Questionnaires (PedEyeQ). METHODS: A total of 1,037 children with an eye condition and 254 visually normal controls, across 0-4, 5-11, and 12-17 years age groups, completed the following questionnaires: Child PedEyeQ (Functional Vision, Bothered by Eyes/Vision, Social, Frustration/Worry domains), Proxy PedEyeQ (same domains plus Eye Care), and Parent PedEyeQ (Impact on Parent and Family, Worry about Child's Eye Condition, Worry about Child's Self-perception and Interactions, and Worry about Functional Vision domains). The primary eye condition was classified as amblyopia (n = 171), cataract (n = 99), cerebral visual impairment (CVI; n = 50), cornea (n = 20), eyelid (n = 35), glaucoma (n = 24), nystagmus (n = 57), orbital (n = 19), pupil/iris (n = 7), refractive error (n = 119), retina (n = 82), strabismus (n = 332), and uveitis (n = 22). RESULTS: PedEyeQ domain scores (scaled 0-100) were significantly worse across eye conditions, compared with controls. Child PedEyeQ greatest differences were on the Bothered by Eyes/Vision domain (nystagmus 5-11 years, -26 points [95% CI, -39 to -12]; nystagmus 12-17 years, -45 [95% CI, -61 to -28]). Proxy PedEyeQ differences were greatest on Functional Vision (CVI 0-4 years, -45 [95% CI, -56 to -34]; CVI 5-11 years, -58 [95% CI, -72 to -43]; nystagmus 12-17 years, -50 [95% CI, -69 to -31]). Parent PedEyeQ differences were greatest on Worry about Child's Functional Vision (CVI 0-4 years, -64; 95% CI -77 to -50). CONCLUSIONS: The PedEyeQ detects reduced ER-QOL and functional vision across pediatric eye conditions, and across age groups, indicating its utility for clinical practice and clinical trials.
PURPOSE: To evaluate eye-related quality of life (ER-QOL) and functional vision across a wide range of pediatric eye conditions, using the Pediatric Eye Questionnaires (PedEyeQ). METHODS: A total of 1,037 children with an eye condition and 254 visually normal controls, across 0-4, 5-11, and 12-17 years age groups, completed the following questionnaires: Child PedEyeQ (Functional Vision, Bothered by Eyes/Vision, Social, Frustration/Worry domains), Proxy PedEyeQ (same domains plus Eye Care), and Parent PedEyeQ (Impact on Parent and Family, Worry about Child's Eye Condition, Worry about Child's Self-perception and Interactions, and Worry about Functional Vision domains). The primary eye condition was classified as amblyopia (n = 171), cataract (n = 99), cerebral visual impairment (CVI; n = 50), cornea (n = 20), eyelid (n = 35), glaucoma (n = 24), nystagmus (n = 57), orbital (n = 19), pupil/iris (n = 7), refractive error (n = 119), retina (n = 82), strabismus (n = 332), and uveitis (n = 22). RESULTS: PedEyeQ domain scores (scaled 0-100) were significantly worse across eye conditions, compared with controls. Child PedEyeQ greatest differences were on the Bothered by Eyes/Vision domain (nystagmus 5-11 years, -26 points [95% CI, -39 to -12]; nystagmus 12-17 years, -45 [95% CI, -61 to -28]). Proxy PedEyeQ differences were greatest on Functional Vision (CVI 0-4 years, -45 [95% CI, -56 to -34]; CVI 5-11 years, -58 [95% CI, -72 to -43]; nystagmus 12-17 years, -50 [95% CI, -69 to -31]). Parent PedEyeQ differences were greatest on Worry about Child's Functional Vision (CVI 0-4 years, -64; 95% CI -77 to -50). CONCLUSIONS: The PedEyeQ detects reduced ER-QOL and functional vision across pediatric eye conditions, and across age groups, indicating its utility for clinical practice and clinical trials.
Authors: James R Drover; Joost Felius; Christina S Cheng; Sarah E Morale; Lauren Wyatt; Eileen E Birch Journal: J AAPOS Date: 2007-12-26 Impact factor: 1.220
Authors: Sarah R Hatt; David A Leske; Yolanda S Castañeda; Suzanne M Wernimont; Laura Liebermann; Christina S Cheng-Patel; Eileen E Birch; Jonathan M Holmes Journal: Am J Ophthalmol Date: 2019-01-14 Impact factor: 5.258
Authors: V K Tailor; Y Abou-Rayyah; J Brookes; P T Khaw; M Papadopoulos; G G W Adams; C Bunce; A Dahlmann-Noor Journal: Eye (Lond) Date: 2017-01-27 Impact factor: 3.775
Authors: David A Leske; Sarah R Hatt; Yolanda S Castañeda; Suzanne M Wernimont; Laura Liebermann; Christina S Cheng-Patel; Eileen E Birch; Jonathan M Holmes Journal: Am J Ophthalmol Date: 2019-08-01 Impact factor: 5.258
Authors: Ying Pan; Kristina Tarczy-Hornoch; Susan A Cotter; Ge Wen; Mark S Borchert; Stanley P Azen; Rohit Varma Journal: Optom Vis Sci Date: 2009-06 Impact factor: 1.973
Authors: David A Leske; Sarah R Hatt; Yolanda S Castañeda; Suzanne M Wernimont; Laura Liebermann; Christina S Cheng-Patel; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2020-02-28 Impact factor: 1.220
Authors: Sarah R Hatt; David A Leske; Yolanda S Castañeda; Suzanne M Wernimont; Laura Liebermann; Christina S Cheng-Patel; Eileen E Birch; Jonathan M Holmes Journal: JAMA Ophthalmol Date: 2020-05-01 Impact factor: 7.389
Authors: Sarah R Hatt; David A Leske; Suzanne M Wernimont; Erick D Bothun; Eileen E Birch; Jonathan M Holmes Journal: J Binocul Vis Ocul Motil Date: 2022-02-01
Authors: David A Leske; Sarah R Hatt; Yolanda S Castañeda; Suzanne M Wernimont; Christina S Cheng-Patel; Erick D Bothun; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2021-06-26 Impact factor: 1.325